Press Release
Candel Therapeutics (NASDAQ: CADL) Lead Candidate CAN-2409 Combats Lung, Pancreatic And Prostate Cancers With Fast Track Designation For Three Cancers
–News Direct–
By Jeremy Golden, Benzinga

Immunotherapy has transformed the way cancer is treated, but just 20% to 40% of patients typically respond to FDA-approved immune checkpoint inhibitor (ICI) treatments.
Poor ICI treatment response has been linked to the tumors ability to disguise antigen presentation and generate an immunosuppressive microenvironment. In addition, most conventional immunotherapies are not designed to educate the patients immune system on how to recognize a variety of tumor antigens and neoantigens.
Amid this landscape, a clinical-stage biopharmaceutical company has developed a new multimodal biological approach that leverages the ability of viral gene constructs to activate cancer-killing mechanisms, exposing multiple tumor antigens to the immune system, resulting in vaccination against the tumor while inhibiting the immunosuppressive tumor microenvironment.
Candel Therapeutics, Inc. (NASDAQ: CADL) is developing a product candidate that is being studied in lung, pancreatic and prostate cancers. Candels most advanced viral immunotherapy candidate, CAN-2409, is an investigational off-the-shelf replication-defective adenovirus designed to induce an individualized, systemic immune response against the patients own tumor.
Part of the companys adenovirus platform, CAN-2409 is injected directly into the tumor or target tissue using a localized injection, akin to the standard approach for vaccination.
CAN-2409's adenoviral construct serves as a vector to transport the HSV-thymidine kinase gene into tumor cells at the site of injection. These tumor cells can then express HSV-thymidine kinase, which converts generic, FDA-approved anti-herpes drugs such as ganciclovir, acyclovir and valacyclovir into a toxic nucleotide analog that blocks DNA synthesis in dividing cells.
Cancer cells exposed to the toxic nucleotide analog in the tumor microenvironment have been observed to undergo immunogenic cell death. Simultaneously, the adenoviral serotype 5 capsid protein elicits a strong pro-inflammatory signal in the tumor microenvironment, creating the optimal conditions to induce a specific CD8+ T cell-mediated response against the injected tumor and uninjected distant metastases for broad and systemic anti-tumor activity.
CAN-2409 is currently being studied in an open-label, phase 2 clinical trial in non-small cell lung cancer (NSCLC) and in randomized, controlled, blinded phase 2b and phase 3 clinical trials in prostate cancer. The company has recently released very encouraging data for CAN-2409s ability to improve overall survival in non-metastatic pancreatic cancer, with topline overall survival data in non-small cell lung cancer planned for this quarter (Q2 2024) and results from the prostate clinical trials later this year (Q4 2024).
When it comes to NSCLC, the company previously presented data from the phase 2 clinical trial in which patients received two administrations of CAN-2409 plus prodrug. Those patients demonstrated the following:
1) Increased infiltration of CD8+ cytotoxic T cells in the tumor microenvironment, systemic expansion of effector T cells and increased soluble granzyme B levels in peripheral blood;
2) Favorable changes in the trajectory of tumor progression;
3) Decreased tumor size of target lesions in most patients; and
4) Reduced size of uninjected tumor lesions.
The CAN-2409 immunotherapy antitumor strategy aims to increase the number of long survivors beyond 10 to 13 months.
As previous work has shown that progressive disease could be converted into stable disease in most patients with non-small cell lung cancer after CAN-2409 treatment, the hypothesis is that this will translate into improved survival.
When it comes to pancreatic cancer, the company reported notable improvements in patients with borderline resectable pancreatic ductal adenocarcinoma (PDAC) after experimental treatment with CAN-2409. The estimated overall survival rate was 71.4% at 24 months in CAN-2409-treated patients versus only 16.7% in the control arm after chemoradiation.
In 2023, CAN-2409 received Fast Track Designation for both non-small cell lung cancer and pancreatic cancer, a validation from the FDA on its potential. CAN-2409 plus valacyclovir in combination with continued PD-1/PD-L1 agents is being evaluated in an ongoing, open-label phase 2 clinical trial in patients with late-stage NSCLC and an inadequate response to anti-PD(L)-1 therapy. In 2024, CAN-2409 also received Orphan Drug Designation from the FDA for CAN-2409 in borderline resectable pancreatic cancer.
In the upcoming year, Candel plans to announce data readouts for the following:
1) Phase 2 topline overall survival (OS) data for CAN-2409 in NSCLC, expected in Q2 2024;
2) Phase 2 topline data for CAN-2409 in low-to-intermediate-risk, localized, non-metastatic prostate cancer, expected in Q4 2024;
3) Phase 3 topline data for CAN-2409 in localized intermediate/high-risk prostate cancer, expected in Q4 2024.
Featured photo by National Cancer Institute on Unsplash.
Candel is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is currently in ongoing clinical trials in non-small cell lung cancer (NSCLC) (phase 2), borderline resectable pancreatic cancer (phase 2), and localized, non-metastatic prostate cancer (phase 2 and phase 3). CAN-3110 is the lead product candidate from the HSV platform and is currently in an ongoing investigator-sponsored phase 1 clinical trial in recurrent high-grade glioma (HGG). Finally, Candels enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.
This article includes certain disclosures that contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of development programs, including the timing and availability of additional data, key data readout milestones, including CAN-3110 in HGG; expectations regarding the potential benefits conferred by Fast Track Designation; expectations regarding the therapeutic benefit of its programs, including the potential for its programs to extend patient survival; and expectations regarding cash runway and expenditures. The words may, will, could, would, should, expect, plan, anticipate, intend, believe, estimate, predict, project, potential, continue, target and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on managements current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Companys programs; that final data from our pre-clinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Companys ability to efficiently discover and develop product candidates; the Companys ability to obtain and maintain regulatory approval of product candidates; the Companys ability to maintain its intellectual property; the implementation of the Companys business model, and strategic plans for the Companys business and product candidates, and other risks identified in the Companys SEC filings, including the Companys most recent Quarterly Report on Form 10-Q filed with the SEC, and subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Companys views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.
This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.
Contact Details
Aljanae Reynolds
+1 617-916-5445
Company Website
View source version on newsdirect.com: https://newsdirect.com/news/candel-therapeutics-nasdaq-cadl-lead-candidate-can-2409-combats-lung-pancreatic-and-prostate-cancers-with-fast-track-designation-for-three-cancers-458506267
Candel Therapeutics
COMTEX_453480918/2655/2024-06-07T08:28:02
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
MEKAN (MKN) Token Launches Presale on PinkSale: Redefining E-commerce with Crypto-Powered Rewards

The blockchain community is buzzing with the launch of MEKAN (MKN), a groundbreaking cryptocurrency token currently in its presale stage on the PinkSale platform. Designed to merge the power of decentralized finance (DeFi) with real-world utility, MEKAN Pro is revolutionizing the e-commerce industry through its innovative crypto-integrated business model.
Presale Link: https://www.pinksale.finance/launchpad/ethereum/0xcB9dA5297Ad7E7ce405464fDFDE5B14F3Ed6eD82
What is MEKAN (MKN)?
At its core, MEKAN (MKN) is more than just a token — it’s a gateway to a new era of digital commerce. Through the MEKAN Pro platform, users will enjoy a seamless online shopping experience where cryptocurrency is not just accepted, but rewarded.
Key features include:
- Crypto-Based Loyalty Programs – Earn rewards in MKN tokens for purchases and referrals.
- Exclusive Discounts & Benefits – Holders gain access to members-only deals across partner e-commerce sites.
- DeFi Utility – Stake MKN tokens for passive income and governance participation in the ecosystem.
Presale Now Live on PinkSale
The MEKAN presale gives early supporters a rare opportunity to get in at the ground level. With limited tokens available at a fixed price, this phase offers early investors the best possible entry point before the token hits major DEXs.
Tokenomics Snapshot:
- Token Name: MEKAN
- Symbol: MKN
- Chain: Ethereum
- Presale Platform: PinkSale
- Presale Ends: [2025.04.25 00:00 (UTC)
The presale is already generating excitement from both seasoned investors and e-commerce enthusiasts eager to join a project with tangible real-world utility.
Why MEKAN Pro?
“We’re building more than a token — we’re creating a full ecosystem where consumers are empowered and rewarded for their loyalty and spending,” said the MEKAN Pro team. “By integrating crypto into everyday online shopping, we’re paving the way for a future where digital assets play a key role in consumer behavior.”
Join the MEKAN Movement
To participate in the presale and become part of the future of e-commerce, visit the official PinkSale link above.
For more information, updates, and community involvement:
Website: https://mekan-web.netlify.app/
Twitter: https://x.com/MatteoBona88173
Telegram: https://t.me/+Qd-eaqlf7mYxYmE0
About MEKAN Pro
MEKAN Pro is a visionary crypto-eCommerce platform focused on integrating blockchain technology into online shopping experiences. With the MEKAN (MKN) token at its core, the platform offers real-world utility, user empowerment, and an ecosystem designed to benefit both consumers and businesses.
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Origins to Attend TOKEN2049 Conference
As the global crypto ecosystem enters a new phase, TOKEN2049, one of the most influential and trendsetting annual events in the industry, once again becomes the focal point of worldwide attention. This conference is not only a premier gathering of thought leaders in the Web3 space but also a critical platform for in-depth dialogue and strategic collaboration among project teams, investors, developers, policymakers, and media.
This year’s first TOKEN2049 conference will take place in Dubai from April 30 to May 1, expected to attract over 10,000 attendees and more than 500 leading organizations, covering cutting-edge sectors such as DeFi, AI, infrastructure, public blockchains, NFTs, and GameFi.
And we—the Origins blockchain team—are thrilled to officially announce our participation in this TOKEN2049 conference.
About TOKEN2049
TOKEN2049 is more than just an industry conference; it is a breeding ground for ideas and trends. Its speaker lineup has historically included key figures from transformative organizations and investment firms such as Ethereum, Solana, Chainlink, Circle, Binance, Coinbase, a16z, and Paradigm, spanning the entire spectrum from foundational blockchain infrastructure to application ecosystems.
TOKEN2049 not only showcases the future direction of Web3 development but also creates a multifaceted value loop encompassing project showcases, fundraising opportunities, technical exchanges, global talent recruitment, and community expansion. It serves as an amplifier for the global Web3 narrative, offering Origins a prime opportunity to connect on a broader scale.
Origins: Unlocking the Future
Origins is a high-performance mainnet designed for the future of “AI + Edge + DePIN.” Over the past year, we have achieved significant milestones, from building our technical foundation to deploying core ecosystem modules. Our decision to participate in TOKEN2049 is driven by the following considerations:
Globalizing Technical Output and Value Narrative: Origins has made original advancements in AI empowerment, edge computing node scheduling, and DePIN resource incentive mechanisms, with verifiable progress to showcase. Through TOKEN2049’s premier platform, we aim to communicate our technical foundation and narrative logic to the industry, establishing a strong cognitive anchor.
Fostering Multilateral Ecosystem Collaboration: TOKEN2049 brings together leading global infrastructure projects, L2 Rollup teams, AI service providers, decentralized storage networks, and cross-chain bridge solutions. This presents an unparalleled opportunity for Origins to build a collaborative network, enabling seamless connections across data, computing power, and tasks.
Attracting Funding and Resources: We are advancing Origins’ ecosystem fund, developer incentive programs, and decentralized governance model. TOKEN2049 serves as a strategic entry point to connect with long-term investment institutions and ecosystem participants, helping us strengthen community foundations, DAO governance, and liquidity support systems.
Origins’ Global Ambition: Beyond Footsteps, a Strategic Vision
From its inception, Origins has been committed to a globalized approach to both technology and community. Our team comprises technical experts and researchers from the United States, and we have already established strategic partnerships with multiple distributed computing platforms, AI model service providers, and decentralized storage networks. We have also deployed server clusters across several continents in the U.S., with plans to expand further.
Participating in TOKEN2049 marks a significant step in Origins’ global strategy, propelling us into the industry’s core discourse circle to engage, collaborate, and co-build with the world’s leading peers.
At the conference, we will showcase Origins’ edge computing scheduling model and AI-powered agent incentive mechanisms, demonstrating how tasks can be published, executed, verified, and rewarded without centralized coordination. We will also share our latest technical roadmap. While we cannot guarantee that the roadmap will remain unchanged in the future, we are committed to ensuring it remains optimal. With technological innovation advancing at a breakneck pace, we are determined to stay ahead of the curve.
TOKEN2049: A Starting Point, Not an Endpoint
For Origins, TOKEN2049 is not merely an event to attend—it is a concrete step in executing our global strategy. We look forward to leveraging this conference to achieve value redefinition, ecosystem connectivity, and global brand recognition simultaneously.
Origins firmly believes that in the new era of AI and blockchain convergence, only public blockchains with global technical reach and open collaboration capabilities can truly fulfill the mission of becoming “next-generation decentralized infrastructure.” With TOKEN2049 as our starting point, we will amplify Origins’ voice to the world.
TOKEN2049, we are ready.
Origins, connecting the intelligent world of tomorrow.
Contact Person Name: Peter Wayne
City State: Chicago, United States
Website: https://originspro.com/
Webmail: mailto:rjaynes416@gmail.com
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
Press Release
Michael Emanuele’s “Rehabber Secrets” Tops Amazon Charts, Delivering a Blueprint for Real Estate Project Management Excellence
Canadian author and project management expert offers real-world systems to help homeowners and investors build smarter, faster, and more profitably.
TORONTO, ON – As North America faces rising construction costs, tightening housing supply, and increased demand for rental housing, real estate investors are seeking smarter strategies to manage renovation projects more effectively. Stepping up to meet that need is Canadian project management professional Michael Emanuele, whose newest book, “Rehabber Secrets: The Essential Strategies Every Real Estate Investor Needs to Plan and Manage Successful Property Rehabs”, has become an Amazon #1 bestseller across multiple categories, including Business Systems & Planning, Project Management, and Home Remodeling & Renovation.
“Many investors know how to buy properties. But managing a renovation is where things often fall apart,” says Michael Emanuele. “This book is about turning chaos into clarity, and helping everyday investors renovate like pros.”
Actively involved in over $100 million of completed commercial and residential projects, Michael Emanuele brings a rare combination of architectural knowledge and construction know-how to an industry in need of structure. Rehabber Secrets is a first-of-its-kind playbook that merges enterprise-level project management systems with real estate investing—a space where renovation failure often stems from poor planning, communication breakdowns, and scope mismanagement.
Filling a Critical Gap in the Real Estate Investment World
While countless real estate books emphasize finding deals, using other people’s money (OPM), or financial freedom, Rehabber Secrets targets the execution phase—where profits are either made or lost. Michael emphasizes that failing to plan is planning to fail. The results are missed deadlines, ballooning budgets, and communication breakdowns with contractors. His book flips that script by offering repeatable systems for project planning, contractor coordination, and risk mitigation.
“Many investors are great at finding and funding deals, but when it comes to managing the renovation process, that’s where things fall apart.” says Michael. “Rehabber Secrets helps fill that knowledge gap. It’s walking the walk and talking the talk—applying a system to execute projects with confidence no matter your experience level in construction.”
The book introduces readers to key project management concepts, such as:
- Pre-construction planning and budgeting
- Defining scopes of work into clear work packages
- How to sequence tasks and create realistic timelines
- Subcontractor coordination and communication
- Proactively managing risk to avoid schedule delays and cost overruns
These frameworks aren’t theory—they’re field-tested systems Michael has used to deliver high-performance results in both residential and commercial builds. Readers gain access to strategies typically reserved for high-end construction firms, translated for small-to-midsize real estate projects.
Building Smarter with We Build ADUs
Michael Emanuele’s hands-on experience is also visible through his Ontario-based company, We Build ADUs, a specialized design-build firm that helps homeowners and investors add Additional Dwelling Units (ADUs) to their properties. ADUs are increasingly seen as a solution to Canada’s housing affordability crisis, offering flexible options for multi-generational living, income generation, and gentle urban intensification to take advantage of existing infrastructure while preventing urban sprawl.
With new-housing starts lagging and the cost of real estate rising, Rehabber Secrets arrives at a crucial time. The book provides not only guidance, but a strategic lens on how infill housing and smaller-footprint construction projects can be executed professionally. At We Build ADUs, Michael brings his project management discipline and architectural background into every client engagement, helping them navigate zoning, building permits, planning and construction—all with a transparent, step-by-step process.
Industry Recognition and Growing Influence
Since its release, Rehabber Secrets has received acclaim from professionals across the real estate and construction sectors. It climbed to the #1 spot in Amazon’s Project Management, Business Systems & Planning, and Home Remodeling & Renovation categories and earned a #2 ranking in Real Estate. The book has been praised for its clarity, actionable insights, and the strength of its real-world examples. It’s solidified its place as the go-to manual for real estate professionals looking to improve their property rehab results.
“Rehabber Secrets isn’t about flipping houses,” Michael Emanuele adds. “It’s about building systems that protect time, money, and peace of mind.”
Michael Emanuele’s growing impact in the field has led to speaking invitations at the Region of Waterloo’s Homes for All Summit, as well as national podcasts, real estate workshops, and professional development seminars when he shares his project management secrets—a sorely missing piece in many real estate education programs. His voice is increasingly recognized as an authority on bridging housing policy with on-the-ground execution—especially in the areas of small-scale development and project management.
A Blueprint That Delivers Results
Rehabber Secrets builds on the foundation of Michael Emanuele’s first book, Rehabbing Your Way to Wealth, but takes a significant leap forward. The new book offers a full project management roadmap, adapted for the realities of investors who manage their own construction—whether full-time or on the side.
For newer investors, it removes the guesswork. For seasoned developers, it introduces systems that can improve scalability. And for professionals supporting clients—designers, realtors, lenders—it serves as a shared language for how great projects get delivered.
“My goal has always been to help people avoid the costly mistakes I’ve seen too many investors make,” says Michael Emanuele. “This book is about giving people a time-tested and repeatable formula to manage their own projects with confidence—turning them into project champions.”
About Michael Emanuele:
Michael Emanuele is a Canadian architectural technologist, project management expert, and the founder of We Build ADUs. He is also the author of Rehabber Secrets, an Amazon #1 bestselling book, and a sought-after speaker on the topics of housing accessibility, construction efficiency, and small-scale urban intensification.
Learn more about Michael’s services at: www.WeBuildADUs.ca
About Author
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.
-
Press Release3 days ago
From $10K to a Global Action Trilogy: Maria Tran’s Echo 8 Saga Redefines Indie Cinema
-
Press Release5 days ago
FXSentry New Trading Strategy Launching: The Guardian Forex Robot Designed for Capital Protection
-
Press Release7 days ago
Dr Hala Medical Aesthetics Introduces New Holistic Approach to Enhance Wellness and Beauty
-
Press Release4 days ago
Meana Raptor Announces Presale with Real-World Utility, NFT Integration, and Anti-Whale Protections
-
Press Release5 days ago
BLENIX TECHNOLOGY Launches BLENIX CHAIN: A Purpose-Driven Blockchain for Real-World Sustainability
-
Press Release7 days ago
Bit.com Exchange Ushers in a New Era of Cloud Mining – C2C Hashrate Trading Now Live
-
Press Release4 days ago
We Row For William: Family of 6-Year-Old Boy with Terminal Illness Launches Urgent Campaign to Fund Life-Saving Gene Therapy
-
Press Release6 days ago
Bali Harmony Rehab Adopts Trauma-Informed, Holistic Model for Addiction and Mental Health Recovery